October 13, 2022
BioTissue Presents Scientific Research at SAWC Fall 2022
Studies Find BioTissue Neox 1K Effective in Healing Diabetic Foot Ulcers and Post-Traumatic, Complex Wounds
MIAMI, October 12, 2022—At this week’s Symposium on Advanced Wound Care (SAWC) in Las Vegas, clinical researchers will present posters summarizing studies that demonstrate the effectiveness of BioTissue Neox® 1K human amniotic allografts in the management of complex foot ulcers and post-traumatic, complex wounds. BioTissue is a pioneer in the application of cryopreserved human birth tissue products for regenerative healing of chronic wounds, musculoskeletal conditions, and ocular surface disease and disorders.
“BioTissue is committed to investing in clinical research that continues to advance our mission of leveraging the unmatched power of amniotic tissue for regenerative healing,” said BioTissue CEO Ted Davis. “These studies support the effectiveness of our innovative products as we strive to help doctors elevate the standard of wound care and positively impact patients’ lives.”
On Saturday, October 15, two BioTissue-focused posters will be available for viewing:
Limb Salvage with Cryopreserved Umbilical Amnion in Patients with Complex Foot Ulcers
Aziz Rasooli, DPM, MS, AACFAS, Los Angeles Bone and Joint Orthopedic Institute
More than 73,000 amputations are performed in diabetic patients annually in the United States, 50-70% of which occur in patients with diabetic foot ulcers, especially those with exposed bone, tendon, muscle, and/or joint capsule, gangrene, and infection.
This study examines three cases in which patients were recommended for below knee amputation presenting with complex, non-healing, infected diabetic foot ulcers. Instead, the patients were treated with debridement and BioTissue Neox 1K amniotic allograft in the operating room. Granulation tissue formation was observed post-operative in all cases over previously exposed underlying tissue. Split thickness skin grafts were applied at one and two months, resulting in complete wound closure without any minor or major amputation. Ultimately, the use of BioTissue Neox 1K resulted in successful limb salvage.
Adjunctive use of Cryopreserved Umbilical Amnion in the Successful Management of Post-Traumatic, Complex Wounds
Christopher Stewart, MD, Orthopedic Trauma Surgeon, Baptist Medical Center, Little Rock, AR.
Traumatic wounds are a serious and common problem, representing about 5% of all visits to the emergency department. These wounds are extraordinarily difficult to manage if they are complex with exposed bone, muscle, or tendon.
This study evaluates the outcomes of patients with post-traumatic complex wounds managed with BioTissue Neox 1K amniotic allograft used as an adjunct. It features four patient cases, including that of a 25-year-old man who suffered a compound tibia fracture, exposing bone and muscle. Three days after open reduction and internal fixation, debridement and wound closure using BioTissue Neox 1K was performed. Granulation happened within three weeks with complete would closure at three months. The study concluded that adjunctive use of BioTissue Neox 1K promoted complete wound closure, prevented infection, and facilitated functional and aesthetic recovery.
Dr. Rasooli’s and Dr. Stewart’s posters, entries CS-118 and CS-133 respectively, are open for viewing on Saturday, October 15 from 9 a.m. to 3 p.m. at SAWC Fall 2022 at Caesar’s Palace, Room Julius 12. The poster awards and reception event is set for 4 p.m.
About BioTissue, Inc.
BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues biologics license applications for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 680,000 human implants with its products and published over 380 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at biotissue.com.
McDougall Communications for BioTissue
[email protected] (585) 434-2154